热门资讯> 正文
4DT在4D-150湿AMD开发日强调4D-150的临床活动和4FRONT第3阶段项目的设计
2024-09-19 04:07
- 4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on longest available follow-up data
- In broad population (Phase 2b), 70% injection-free through 52 weeks
- In severe population (Phase 1/2a), 83% overall reduction in annualized injections through 52 weeks
- 4D-150 continues to be safe and well tolerated with intraocular inflammation (IOI) profile numerically similar (2.8% transient 1+ vitreous cells) to approved anti-VEGF agents
- 4FRONT Phase 3 program designed to maximize 4D-150's potential, including probabilities of clinical, regulatory and commercial success across global markets
- Corporate webcast to be held on September 18, 2024 at 4:15 p.m. ET
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
